Type 2 diabetics will soon have a new treatment option, thanks to FDA’s approval of once-weekly injectable drug Bydureon (exenatide). For the drug’s owner, Amylin Pharmaceuticals Inc., the choices will likely be many as well, as the company faces challenges in gaining market access in a heavily competitive environment.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?